UCLA SPORE in Prostate Cancer

UCLA SPORE 在前列腺癌中的应用

• 批准号: 7879474
• 负责人: ROBERT E REITER
• 金额: $ 230万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-15 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7879474
• 关键词: UCLA; SPORE; Prostate; Cancer

The UCLA Prostate Cancer SPORE program is a multidisciplinary and translational research program whose purpose is to understand the biology of prostate cancer and to develop more effective methods for prevention, diagnosis and treatment. This mission will be accomplished through (1) five major research projects focused on the application of basic and population science to the prevention, diagnosis and treatment of prostate cancer, and (2) the recruitment and development of new prostate cancer researchers and research projects through career development and developmental research projects. The UCLA prostate SPORE leverages the exciting resources and programs at UCLA, its sister institutions, as well as Cedars Sinai and City of Hope Cancer Center, to improve the care of men with prostate cancer. It collaborates extensively with other SPORE institutions and the SPORE program at the NCI to advance local and national initiatives. Over the first four years of funding, the UCLA SPORE has made significant strides, such as the development and translation of PSCA antibody therapy to the clinic, the demonstration at the molecular level that mTOR antagonism down-regulates the PIS kinase-PTEN-Akt pathway in men with PTEN null tumors, and the initiation of a novel dietary prevention trial in men undergoing prostate surgery. In this application, the five major projects are as follows: 1) Project 1: Bioengineered Antibodies Against Prostate Stem Cell Antigen (PSCA) for Prostate Cancer Imaging (Project Leaders: Anna Wu, M.D. and Robert Reiter, M.D; Project co-Leader, Robert Figlin, M.D.); 2) Project 2: Exploiting PIS Pathway Inhibitor Therapy in Prostate Cancer (Project Leaders: Hong Wu, M.D, Ph.D. and Charles Sawyers, M.D; Project co-Leaders, Robert Reiter, M..D. and Howard Scher, M.D; 3) Project 3: Lymphangiogenesis and Metastasis in Prostate Cancer (Project Leader: Lily Wu, M.D., Ph.D; Project co-Leader: David Agus, M.D.); 4) Project 4: Evaluating the role of IGFBP-3 therapy in men with prostate cancer (Project Leader: Pinchas Cohen, M.D.; Project co- Leaders: Alan Pantuck, M.D and Kuk-Wha Lee, M.D., Ph.D; 5) Project 5: Dietary Fat Modulation and targeted Therapies for Prostate Cancer Prevention (Project Leader: William Aronson, M.D.; Project co- Leaders: Pinchas Cohen, M.D. and Harvey Herschman, Ph.D.)

UCLA前列腺癌孢子计划是一项多学科和转化研究计划，其目的是了解前列腺癌的生物学，并开发更有效的预防，诊断和治疗方法。该任务将通过（1）五个主要的研究项目来完成，这些研究重点是将基础和人口科学应用于预防，诊断和治疗前列腺癌，以及（2）通过职业发展和发展研究项目的招募和发展新的前列腺癌研究人员和研究项目。加州大学洛杉矶分校的前列腺孢子利用了UCLA，其姊妹机构以及雪松西奈和希望之城癌症中心的激动人心的资源和计划，以改善对前列腺癌男性的护理。它与NCI的其他孢子机构和孢子计划进行了广泛的合作，以推进本地和国家计划。在最初的四年资金中，UCLA孢子取得了长足的进步，例如PSCA抗体疗法向诊所的开发和翻译，在分子水平上进行的演示MTOR拮抗作用下调了PIS激酶-AKT-AKT在患有PTEN NULL肿瘤的男性中的PIS激酶-AKT途径，以及在新的饮食中进行培养量的启动。在此应用中，五个主要项目如下：1）项目1：针对前列腺癌成像的前列腺干细胞抗原（PSCA）的生物工程抗体（项目负责人：Anna Wu，M.D。和Robert Reiter，M.D; M.D; M.D; Project coe-Leader，Robert Figlin，M.D。）; 2) Project 2: Exploiting PIS Pathway Inhibitor Therapy in Prostate Cancer (Project Leaders: Hong Wu, M.D, Ph.D. and Charles Sawyers, M.D; Project co-Leaders, Robert Reiter, M..D. and Howard Scher, M.D; 3) Project 3: Lymphangiogenesis and Metastasis in Prostate Cancer (Project Leader: Lily Wu, M.D., Ph.D; Project co-Leader:大卫·阿古斯（David Agus），医学博士）； 4) Project 4: Evaluating the role of IGFBP-3 therapy in men with prostate cancer (Project Leader: Pinchas Cohen, M.D.; Project co- Leaders: Alan Pantuck, M.D and Kuk-Wha Lee, M.D., Ph.D; 5) Project 5: Dietary Fat Modulation and targeted Therapies for Prostate Cancer Prevention (Project Leader: William Aronson, M.D.; Project co- Leaders: Pinchas医学博士科恩和哈维·赫斯曼博士）